A Phase 4 interventional study of Rapid-Acting Insulin and Long acting insulin in Diabetes Mellitus and Type 1 Diabetes, sponsored by Emory University. Completed at 1 site in United States. Open to participants aged 7 Years to 15 Years. Per ClinicalTrials.gov, last updated 2021-09-30.
Sponsored by Emory University · Phase 4, Interventional, and Treatment
Type 1 diabetes mellitus (T1DM) is a challenging medical disorder, especially in children and adolescents. In order to prevent the chronic complications of hyperglycemia, the maintenance of near-normal glycemic control must be balanced with minimizing hypoglycemia. Although many pediatric endocrinologists provide an ICR plan for their newly diagnosed patients with T1DM, fixed dosing and other forms of insulin delivery are available. This proposal is designed to compare children and adolescents with newly diagnosed T1DM using a fixed insulin dose for fixed carbohydrate mealtime regimen (FIXED group) to children and adolescents with newly diagnosed T1DM using an ICR with variable carbohydrate intake (ICR group) mealtime regimen. In addition to determining the feasibility for a subsequently larger clinical trial, the aims of this investigator-initiated, prospective proposal, is twofold. The first is to determine if the caregivers of diabetics using a fixed insulin for fixed carbohydrate regimen (FIXED group) experience less anxiety than the caregivers of those using an ICR with variable carbohydrate intake regimen (ICR group) at 1- and 4-months post-randomization. The second is to determine if diabetics utilizing a fixed insulin for fixed carbohydrate regimen (FIXED group) have decreased glycemic variability (GV) than those using an ICR with variable carbohydrate intake regimen (ICR group) at 1- and 4-months post-randomization.
Although children and adolescents with T1DM have much more freedom with the amount of food (carbohydrates) they eat while using an ICR at mealtime, the difficulty in determining the amount of insulin needed, how and when to adjust the ICR, the difficulty with understanding the basics of managing T1DM, and the adaptation to a new lifestyle with T1DM may be more complicated than utilizing a simple plan that includes a fixed amount of insulin and fixed number of carbohydrates, at least for the first few months after diagnosis. As complicated as it is for children, adolescents, and their caregivers to learn how to manage T1DM after being discharged home in usually \< 48 hours after diagnosis, a more simplified insulin regimen at mealtime may provide the family of and the child or adolescent with newly diagnosed T1DM with less stress and anxiety while still maintaining adequate glycemic control. Twenty - 40 subjects will be recruited at Children's Hospital of Atlanta (CHOA) at Egleston and will be randomized to either the FIXED group or the ICR group according to a computer-generated random sampling table. The subject and his/her caregivers will receive diabetes education while in the hospital in standard fashion. The subject and his/her caregivers will receive glucose monitoring education and training prior to hospital discharge. The subject and his/her caregivers will also receive a paper log to record the blood sugars, number of carbohydrates consumed and insulin administered at each meal throughout the day.
Prior to discharge, all subjects will receive a regimen that includes a: 1) Meal-time insulin and carbohydrate regimen (# of units of insulin, # of carbohydrates, and/or ICR); 2) Daily dose of Glargine; 3) Hyperglycemia correction regimen for blood glucose levels > 199 mg/dL; and 4) Hypoglycemia treatment regimen for blood glucose levels \< 70 mg/dL and/or symptomatic.
As per standard diabetes care, caregivers will report all blood glucose levels every day (to the study investigators) until the subject's initial clinic visit 4-6 weeks after diagnosis. All insulin adjustments will be made by the study investigators.
After the subject's first clinic visit, caregivers will contact the study investigators once a week to report blood glucose levels and the investigators will make adjustments as needed.
All the diabetes clinic visits will occur at the Center for Advanced Pediatrics (CAP), approximately three miles from CHOA-Egleston Hospital. Subjects will attend clinic with one or more of the investigators approximately 1 and 4 months after enrollment.
At each clinic visit, subjects (and their caregivers) will answer standard diabetes questions, subjects will undergo a physical examination, and subjects' objective data (vital signs, glucose meter (GM) data, insulin dosing, and carbohydrate intake) will be collected by the study personnel.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 24 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Emory University is the lead sponsor of 1,386 studies on the registry; 236 are open to participants now.
Of its 229 completed or terminated interventional studies of FDA-regulated products, 174 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.
Drug: Rapid-Acting Insulin · Drug: Long acting insulin
Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen
Drug: Rapid-Acting Insulin · Drug: Long acting insulin
Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)
Also known as: Lispro, Aspart, glulisine
Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)
Also known as: Glargine
Number of All Consented Participants
The capacity for recruitment was assessed, including all subjects that signed the Informed Consent Form (ICF).
Time frame: 4 months post-intervention
Number of Participants That Completed All Visits
Number of participants that were able to complete all study visits, including the visits in-person at 1 month and 4 months post-randomization.
Time frame: 4 months post-intervention
Caregiver Treatment Adherence at 1 Month and 4 Months Post-intervention
Caregiver treatment adherence was assessed using a blood glucose log. Subjects and caregivers recorded blood glucose levels and the amount/type of insulin given. This data was used to calculate adherence as a percentage ranging from 0% (no adherence) to 100% (full adherence).
Time frame: 1 month post-intervention and 4 months post-intervention
Caregiver Anxiety
Caregiver anxiety was measured with the "parental stress scale". Caregivers completed the "parental stress scale" at initial enrollment and at each clinic follow up visit. The Parental Stress Scale includes 18 questions that are rated from 1 (strongly disagree) to 5 (strongly agree). Scoring ranges from 18 - 90. The higher the score, the higher the stress and anxiety level.
Time frame: Baseline, 1 month post-intervention, 4 months post-intervention
Glycemic Variability (GV) at 1 Month and 4 Months Post-intervention
The GV was calculated in all subjects using the average blood glucose levels collected from the daily blood glucose paper log. A subjective qualification system was used to label each subject's GV based on their blood glucose levels and an established glucose monitoring (GM) data system. Subjects are considered to have appropriate GV if their blood glucose levels are in the range of 80 mg/dL - 180 mg/dL. Percentage of participants within each specific average BG range is shown.
Time frame: 1 month post-intervention, 4 months post-intervention
| Milestone | Fixed Group | Insulin to Carbohydrate Ratio (ICR) Group |
|---|---|---|
| Started | 12 | 12 |
| Completed | 11 | 10 |
| Not completed | 1 | 2 |
| Withdrew: Moved out of state | 0 | 2 |
| Withdrew: Did not show up to the follow-up appointment | 1 | 0 |
The capacity for recruitment was assessed, including all subjects that signed the Informed Consent Form (ICF).
| Participants | Fixed Group | Insulin to Carbohydrate Ratio (ICR) Group |
|---|---|---|
| Number of All Consented Participants | 12 | 12 |
Number of participants that were able to complete all study visits, including the visits in-person at 1 month and 4 months post-randomization.
| Participants | Fixed Group | Insulin to Carbohydrate Ratio (ICR) Group |
|---|---|---|
| Number of Participants That Completed All Visits | 11 | 10 |
Caregiver treatment adherence was assessed using a blood glucose log. Subjects and caregivers recorded blood glucose levels and the amount/type of insulin given. This data was used to calculate adherence as a percentage ranging from 0% (no adherence) to 100% (full adherence).
| percentage of participants | Fixed Group | Insulin to Carbohydrate Ratio (ICR) Group |
|---|---|---|
| < 4 times/day at 1-month visit | 3.2 (0.0 to 16.1) | 10.2 (2.4 to 21.4) |
| ≥ 4 times/day at 1-month visit | 96.8 (83.9 to 100) | 89.8 (78.6 to 97.6) |
| < 4 times/day at 4-month visit | 2.6 (0.0 to 12.6) | 16.1 (2.0 to 39.2) |
| ≥ 4 times/day at 4-month visit | 97.0 (87.4 to 100) | 83.9 (61.8 to 98.0) |
Caregiver anxiety was measured with the "parental stress scale". Caregivers completed the "parental stress scale" at initial enrollment and at each clinic follow up visit. The Parental Stress Scale includes 18 questions that are rated from 1 (strongly disagree) to 5 (strongly agree). Scoring ranges from 18 - 90. The higher the score, the higher the stress and anxiety level.
| score on a scale | Fixed Group | Insulin to Carbohydrate Ratio (ICR) Group |
|---|---|---|
| Baseline | 29.1 (24.3 to 34.0) | 30.2 (25.3 to 35.0) |
| 1 month post-intervention | 27.0 (22.2 to 31.8) | 35.9 (30.7 to 41.1) |
| 4 months post-intervention | 27.6 (22.7 to 32.6) | 34.4 (29.3 to 39.4) |
The GV was calculated in all subjects using the average blood glucose levels collected from the daily blood glucose paper log. A subjective qualification system was used to label each subject's GV based on their blood glucose levels and an established glucose monitoring (GM) data system. Subjects are considered to have appropriate GV if their blood glucose levels are in the range of 80 mg/dL - 180 mg/dL. Percentage of participants within each specific average BG range is shown.
| percentage of participants | Fixed Group | Insulin to Carbohydrate Ratio (ICR) Group |
|---|---|---|
| BG < 50 mg/dL at 1 month post-intervention | 0.5 (0.0 to 0.6) | 0.5 (0.0 to 0.7) |
| BG 50-79 mg/dL at 1 month post-intervention | 8.9 (4.7 to 14.7) | 8.3 (5.2 to 10.0) |
| BG 80-180 mg/dL at 1 month post-intervention | 67.5 (48.9 to 70.0) | 63.2 (54.0 to 74.6) |
| BG 181-350 mg/dL at 1 month post-intervention | 25.8 (13.3 to 37.7) | 26.8 (17.1 to 34.0) |
| BG >350 mg/dL at 1 month post-intervention | 0.8 (0.0 to 1.6) | 0.3 (0.0 to 2.0) |
| BG < 50 mg/dL at 4 month post-intervention | 0.0 (0.0 to 0.2) | 0.4 (0.0 to 1.5) |
| BG 50-79 mg/dL at 4 month post-intervention | 8.6 (5.3 to 12.4) | 7.3 (4.2 to 11.4) |
| BG 80-180 mg/dL at 4 month post-intervention | 63.3 (57.1 to 80.4) | 69.0 (59.5 to 75.9) |
| BG 181-350 mg/dL at 4 month post-intervention | 28.7 (8.2 to 35.5) | 21.8 (5.8 to 28.0) |
| BG >350 mg/dL at 4 month post-intervention | 0.1 (0.0 to 0.8) | 0.4 (0.0 to 2.7) |
Collected over Data collected during follow up (until 4 months post-intervention).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fixed Group | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Insulin to Carbohydrate Ratio (ICR) Group | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Event | Fixed Group | Insulin to Carbohydrate Ratio (ICR) Group |
|---|---|---|
| Severe HypoglycemiaMetabolism and nutrition disorders | 0/12 | 0/12 |
| Altered Mentas StatusGeneral disorders | 0/12 | 0/12 |
| Diabetic KeoacidosisMetabolism and nutrition disorders | 0/12 | 0/12 |
| Age, Continuous(years) | Fixed Group | Insulin to Carbohydrate Ratio (ICR) Group | Total |
|---|---|---|---|
| Median | 10 (9 to 12.5) | 11 (9 to 12) | 11 (9 to 11.3) |
| Sex: Female, Male(Participants) | Fixed Group | Insulin to Carbohydrate Ratio (ICR) Group | Total |
|---|---|---|---|
| Female | 5 | 8 | 13 |
| Male | 7 | 4 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Fixed Group | Insulin to Carbohydrate Ratio (ICR) Group | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 4 |
| Not Hispanic or Latino | 10 | 10 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Fixed Group | Insulin to Carbohydrate Ratio (ICR) Group | Total |
|---|---|---|---|
| United States | 12 | 12 | 24 |
| Onset with Acidosis(Participants) | Fixed Group | Insulin to Carbohydrate Ratio (ICR) Group | Total |
|---|---|---|---|
| Yes | 8 | 8 | 16 |
| No | 4 | 4 | 8 |
| Pubertal at onset(Participants) | Fixed Group | Insulin to Carbohydrate Ratio (ICR) Group | Total |
|---|---|---|---|
| Yes | 5 | 5 | 10 |
| No | 7 | 7 | 14 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Emory University